Table 5. Parameters associated with the complete control state (UAS7 = 0).

Variables (n = 108)		OR	95% CI	P value
Age (yr)		0.978	0.941–1.016	0.247
Sex (female)		1.863	0.691–5.026	0.219
BMI (kg/m2)		1.003	0.877–1.148	0.959
Duration of CU (mon)		1.001	0.993–1.009	0.857
ASST positivity (n = 81)		2.304	0.778–6.824	0.132
Total IgE (kU/mL)		1.000	0.999–1.001	0.964
Total IgE group
	Normal (0–114)	Ref.
	High (> 114)	1.000	0.392–2.551	1.000
CU symptom score at visit 1
	UAS7 (0–42)	0.974	0.925–1.026	0.329
	K-UCT (0–16)	1.299	1.087–1.553	0.004
	CU-QOL (0–100)	1.031	1.002–1.061	0.036
	Patient’s VAS (0–100)	0.983	0.967–1.000	0.050
Treatment types				0.025
	Updosing 4 folds	Ref.
	Multiple combination	0.180	0.043–0.760	0.020
	Standard dose nsAHs	0.293	0.100–0.858	0.025

ASST, autologous serum skin test; BMI, body mass index; CI, confidential interval; CU, chronic urticaria; CU-QOL, chronic urticaria-specific quality of life; IgE, immunoglobulin E; K-UCT, Korean version of urticaria control test; nsAH, nonsedating H₁-antihistamine; OR, odds ratio; UAS7, urticaria activity score over 7 days, VAS, visual analogue scale.